obstructive sleep apnea-hypopnea syndrome
Conditions
Interventions
Esketamine (ES) group:Esketamine 0.1 ml/kg was administered intravenously at induction of anesthesia and 0.2 ml/ kg/h was administered intraoperatively by continuous intravenous infusion of esketamine
Control (N) group:Saline 0.1 ml/kg was administered at induction of anesthesia and 0.2 ml/ kg/h was administered intraoperatively by continuous intravenous infusion of saline.
Sponsors
Shanghai Children’s Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 7 Years
Inclusion criteria
Inclusion criteria: 1. ASA Level I-II 2. Age 3-7 years 3. Body mass index (BMI) =15.5 kg/m2 and =24.5 kg/m2 with weight over 12 kg
Exclusion criteria
Exclusion criteria: 1. Hypersensitivity to the drugs used in this study or opioid abuse 2.Severe obstructive sleep apnea syndrome and cardiac arrhythmia. 3.Combined serious cardiac, hepatic, renal dysfunction and mental abnormality. 4. Fever higher than 38°C or acute upper respiratory tract infection and bronchial asthma in the 24 hours before surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of moderate to severe pain on swallowing over 6 hours; | — |
Secondary
| Measure | Time frame |
|---|---|
| FLACC scores at rest and during swallowing at 0.5h, 2h, 4h, 6h, 12h, and 24h postoperatively;Incidence of agitation while in the PACU in both groups of children;Dosage of the remedial drug nalbuphine;Additional consumption of intraoperative remifentanil;Quality of sleep at night on the day of surgery;Time to extubation (defined as the time between the end of the procedure and extubation);Incidence of postoperative adverse effects (delayed awakening, nausea and vomiting, hypertension, hypotension, tachycardia, low finger pulse oximetry (less than 90), respiratory depression, delirium, dizziness, pruritus, constipation); | — |
Countries
China
Contacts
Public ContactYu Shenghua
Department of Anesthesiology, Shanghai Children’s Hospital
Outcome results
None listed